Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.
Rheumatoid arthritis (RA) is a long-term autoimmune disorder causing inflammation, pain, and swelling in joints, typically the hands and wrists, and often on both sides of the body.
